GO:1903006 positive regulation of protein K63-linked deubiquitination: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903006 describes any process that activates or increases the frequency, rate or extent of protein K63-linked deubiquitination.
• K63-linked deubiquitination is catalyzed by deubiquitinases (DUBs) such as USP1, USP3, USP10, UCHL1, and STAMBPL1, which remove K63-linked polyubiquitin chains from target proteins [1,2,3,5,4].
• Positive regulation of this process stabilizes key signaling proteins, including MAST1, ANLN, SMARCA5, TOE1, Twist1, and ERα, thereby influencing cancer progression and therapy resistance [1,2,3,4,5,7].
• Dysregulation of K63-linked deubiquitination is implicated in cisplatin resistance, esophageal squamous cell carcinoma, prostate cancer, hepatocellular carcinoma, and breast cancer endocrine resistance [1,2,3,4,7].
• CRISPR/Cas9 genome-wide screening has identified DUB subfamily members, such as USP1, as critical regulators of K63-linked deubiquitination and drug resistance.
• Experimental models including knockout, point-mutation, knock-in, and overexpression cell lines are essential to dissect the causal roles of DUBs in this process [1,2,3,5].
Description
Protein K63-linked deubiquitination is a reversible post-translational modification that removes K63-linked polyubiquitin chains from substrate proteins, thereby altering their stability, localization, or interaction partners [1,2]. The positive regulation of this process, annotated as GO:1903006, encompasses any molecular event that enhances the activity or recruitment of deubiquitinases (DUBs) toward K63-linked chains [1,3]. This regulatory mechanism is critical for maintaining protein homeostasis and controlling signaling pathways that drive cancer and other diseases [2,4]. Recent studies have identified several DUBs, including USP1, USP3, USP10, UCHL1, and STAMBPL1, that positively regulate K63-linked deubiquitination of specific substrates such as MAST1, SMARCA5, ANLN, Twist1, and TOE1 [1,2,3,4,5]. These findings highlight the importance of GO:1903006 in oncology and provide a framework for developing targeted therapies. Understanding the molecular players and regulatory networks of K63-linked deubiquitination is essential for researchers aiming to manipulate this process in disease models.
positive regulation of protein K63-linked deubiquitination At A Glance
| GO ID | GO:1903006 |
|---|---|
| GO term | positive regulation of protein K63-linked deubiquitination |
| Ontology | biological_process |
| Synonym | activation of protein K63-linked deubiquitination; up regulation of protein K63-linked deubiquitination; up-regulation of protein K63-linked deubiquitination; upregulation of protein K63-linked deubiquitination |
| Major function | Enhances the removal of K63-linked ubiquitin chains from substrate proteins, thereby modulating protein stability and signaling [1,2]. |
| Key enzymes | Deubiquitinases (DUBs) including USP1, USP3, USP10, UCHL1, STAMBPL1 [1,2,3,5,4]. |
| Substrate examples | MAST1, ANLN, SMARCA5, TOE1, Twist1, ERα [1,2,3,4,5,7]. |
| Disease relevance | Cancer drug resistance, metastasis, and endocrine resistance [1,2,3,4,5,7]. |
| Research methods | CRISPR screening, knockout/knock-in models, proteomics, and ubiquitination assays [1,3,8]. |
What Is GO:1903006?
GO:1903006, positive regulation of protein K63-linked deubiquitination, is defined as any process that activates or increases the frequency, rate or extent of the removal of K63-linked ubiquitin chains from a target protein. This biological process is mediated by deubiquitinating enzymes (DUBs) that specifically cleave K63-linked polyubiquitin, thereby reversing the effects of K63-linked ubiquitination [2,3]. Positive regulation can occur through increased DUB expression, post-translational modifications of DUBs, or recruitment of DUBs to substrate proteins [4,5].
Why Is positive regulation of protein K63-linked deubiquitination Important in Cell Biology?
GO:1903006 is important because K63-linked deubiquitination controls the stability and function of proteins that are central to DNA damage response, cell cycle regulation, and oncogenic signaling [1,3,4]. Dysregulation of this process can lead to chemotherapy resistance, tumor progression, and metabolic reprogramming in cancer [2,5,7]. Moreover, positive regulators of K63-linked deubiquitination, such as USP1 and USP10, have emerged as potential therapeutic targets [1,2]. Understanding how these enzymes are regulated provides insights into basic cell biology and offers opportunities for precision medicine.
• Controls protein stability by reversing K63-linked ubiquitination, affecting substrates like MAST1 and ANLN [1,2].
• Modulates DNA damage response and chemotherapy resistance through SMARCA5 stabilization.
• Regulates oncogenic signaling pathways, including EGFR stability via the MYC-STAMBPL1-TOE1 axis.
• Promotes tumor metastasis by stabilizing Twist1 in non-small cell lung cancer.
• Drives endocrine resistance in breast cancer by stabilizing ERα.
• Negatively regulates innate immune signaling by attenuating K63-linked ubiquitination of STING.
• Involved in ribosome quality control through polyubiquitin architecture editing.
• Provides targets for CRISPR-based functional genomics and drug discovery.
What Happens During positive regulation of protein K63-linked deubiquitination?
Recognition of K63-linked ubiquitin chains
In simple terms: The deubiquitinase enzyme finds and binds to the K63-linked ubiquitin chain on a target protein.
Positive regulation begins with the recruitment of a DUB to a substrate carrying K63-linked polyubiquitin. For example, USP1 is recruited to MAST1 to remove K63-linked chains, thereby stabilizing MAST1 and promoting cisplatin resistance. Similarly, USP10 binds ANLN and removes K63-linked ubiquitin, leading to ANLN degradation in esophageal squamous cell carcinoma. The specificity of recognition is often mediated by adaptor proteins or post-translational modifications on the DUB.
Catalytic cleavage of K63-linked chains
In simple terms: The enzyme cuts the ubiquitin chain off the target protein.
Once bound, the DUB catalyzes the hydrolysis of the isopeptide bond between the C-terminal glycine of ubiquitin and lysine 63 of the distal ubiquitin. USP3 deubiquitinates SMARCA5, removing K63-linked chains and stabilizing SMARCA5 to promote DNA damage response. UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination, driving metastasis in non-small cell lung cancer. The catalytic activity of DUBs can be enhanced by interacting partners or post-translational modifications.
Substrate stabilization or functional alteration
In simple terms: Removing the ubiquitin chain changes what the target protein does or how long it lasts.
Deubiquitination of K63-linked chains often prevents proteasomal degradation or alters signaling. For instance, STAMBPL1 deubiquitinates TOE1, leading to TOE1 stabilization and subsequent EGFR stabilization in hepatocellular carcinoma. USP10 deubiquitinates ERα, enhancing its stability and promoting endocrine resistance in breast cancer. In contrast, K63-linked deubiquitination of STING by TRIM35 negatively regulates cGAS-STING signaling.
Feedback and regulatory loops
In simple terms: The process is controlled by feedback loops that can amplify or dampen the signal.
Positive regulation of K63-linked deubiquitination is often embedded in feedback loops. A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma. Similarly, USP1 regulates MAST1-driven cisplatin resistance, and its own expression may be controlled by stress-responsive pathways. These loops ensure precise control of protein homeostasis and can be hijacked in disease.
Key Genes Involved in GO:1903006 positive regulation of protein K63-linked deubiquitination
The following genes and proteins are key players in the positive regulation of protein K63-linked deubiquitination, as supported by recent literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| USP1 | Deubiquitinase that stabilizes MAST1 by removing K63-linked chains | Cisplatin resistance in cancer; CRISPR screening identified USP1 as a regulator |
| USP10 | Deubiquitinates ANLN and ERα, affecting stability | Esophageal squamous cell carcinoma and breast cancer endocrine resistance [2,7] |
| USP3 | Stabilizes SMARCA5 via K63-linked deubiquitination | DNA damage response and chemotherapy resistance in prostate cancer |
| STAMBPL1 | Deubiquitinates TOE1, part of MYC-STAMBPL1-TOE1 feedback loop | EGFR stability in hepatocellular carcinoma |
| UCHL1 | Stabilizes Twist1 via K11/K63-linked deubiquitination | Tumor metastasis in non-small cell lung cancer |
| TRIM35 | Attenuates K63-linked ubiquitination of STING | Negatively regulates cGAS-STING signaling |
| MAST1 | Substrate of USP1; stabilized by K63 deubiquitination | Cisplatin resistance |
| ANLN | Substrate of USP10; degradation induced by deubiquitination | Esophageal squamous cell carcinoma |
| SMARCA5 | Substrate of USP3; stabilized by K63 deubiquitination | DNA damage response |
| TOE1 | Substrate of STAMBPL1; involved in EGFR stability | Hepatocellular carcinoma |
| Twist1 | Substrate of UCHL1; stabilized by K11/K63 deubiquitination | Metastasis in NSCLC |
| ERα | Substrate of USP10; stabilized by deubiquitination | Breast cancer endocrine resistance |
| STING | Substrate of TRIM35; K63-linked ubiquitination attenuated | Innate immune signaling |
| MYC | Transcription factor in MYC-STAMBPL1-TOE1 loop | Hepatocellular carcinoma |
| EGFR | Stabilized downstream of TOE1 | Hepatocellular carcinoma |
| ARL3 | Enhances ERα stability via USP10 deubiquitination | Breast cancer metabolic reprogramming |
How Is positive regulation of protein K63-linked deubiquitination Regulated?
The positive regulation of protein K63-linked deubiquitination is controlled at multiple levels. DUB expression can be induced by oncogenic transcription factors such as MYC, which drives STAMBPL1 expression and creates a positive feedback loop with TOE1 and EGFR. Post-translational modifications of DUBs, such as phosphorylation or ubiquitination, can modulate their activity or substrate specificity [1,3]. Additionally, interacting proteins like ARL3 can enhance USP10-mediated deubiquitination of ERα. In the context of ribosome quality control, polyubiquitin architecture editing on collided ribosomes maintains persistent RQC activity, highlighting a specialized regulatory mechanism. These layers of regulation ensure that K63-linked deubiquitination is tightly controlled in response to cellular stress and signaling cues.
positive regulation of protein K63-linked deubiquitination and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| USP1 | Cisplatin resistance in cancer | Knockout cell lines and xenograft models |
| USP10 | Esophageal squamous cell carcinoma; breast cancer endocrine resistance | Knockout and overexpression models [2,7] |
| USP3 | Prostate cancer chemotherapy resistance | Point mutation and knockout models |
| STAMBPL1 | Hepatocellular carcinoma | Knock-in and knockout models |
| UCHL1 | Non-small cell lung cancer metastasis | Overexpression and knockout models |
Cancer drug resistance
Positive regulation of K63-linked deubiquitination contributes to chemotherapy resistance. USP1 stabilizes MAST1, leading to cisplatin resistance in cancer cells. USP3 promotes DNA damage response and chemotherapy resistance by stabilizing SMARCA5 in prostate cancer. Targeting these DUBs could sensitize tumors to conventional therapies [1,3].
Tumor progression and metastasis
DUBs that enhance K63-linked deubiquitination drive tumor progression. USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma, suggesting a tumor-suppressive role in this context. Conversely, UCHL1 stabilizes Twist1 to promote metastasis in non-small cell lung cancer. The MYC-STAMBPL1-TOE1 feedback loop mediates EGFR stability in hepatocellular carcinoma, supporting tumor growth.
Endocrine resistance and metabolic reprogramming
In hormone receptor-positive breast cancer, ARL3 enhances ERα stability via USP10 deubiquitination, promoting endocrine resistance and mitochondrial metabolic reprogramming. This highlights how K63-linked deubiquitination can rewire cellular metabolism to support therapy resistance.
Innate immunity and inflammation
TRIM35 negatively regulates cGAS-STING-mediated signaling by attenuating K63-linked ubiquitination of STING. This demonstrates that positive regulation of K63-linked deubiquitination can also dampen immune responses, with implications for autoimmune diseases and cancer immunotherapy.
From positive regulation of protein K63-linked deubiquitination-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of USP1 affect MAST1 stability and cisplatin sensitivity? | USP1 knockout cell lines |
| Can point mutations in USP3 catalytic domain abolish SMARCA5 stabilization? | USP3 point-mutation knock-in |
| Does STAMBPL1 overexpression enhance TOE1 and EGFR stability? | STAMBPL1 overexpression and knock-in |
| What is the effect of UCHL1-mediated Twist1 stabilization on metastasis? | UCHL1 knockout and Twist1 tagged knock-in |
| How does ARL3 regulate USP10-mediated ERα deubiquitination? | ARL3 knockout and USP10 overexpression |
| Does TRIM35 attenuate K63-linked ubiquitination of STING? | TRIM35 knockout and STING knock-in |
How to Study the positive regulation of protein K63-linked deubiquitination Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR/Cas9 knockout | Loss-of-function effects on K63-linked deubiquitination | Identify essential DUBs |
| Point mutation knock-in | Catalytic activity and substrate specificity | Dissect DUB mechanism |
| Overexpression | Gain-of-function effects on substrate stability | Model oncogenic roles [4,5] |
| Ubiquitination assay | Removal of K63-linked chains | Validate DUB activity [2,3] |
| Proteomics | Substrate identification and interactome | Discover new players [2,4] |
| Ribo-seq | Translational changes upon DUB modulation | Assess global protein synthesis |
| Imaging | Subcellular localization of DUBs and substrates | Track dynamic regulation |
| Bioinformatics | Pathway enrichment and network analysis | Integrate multi-omics data |
CRISPR/Cas9 genome-wide screening
Genome-wide CRISPR screens can identify DUBs that positively regulate K63-linked deubiquitination. For example, a CRISPR/Cas9-based screen for deubiquitinase subfamily members identified USP1 as a regulator of MAST1-driven cisplatin resistance. This approach enables unbiased discovery of novel regulators and is compatible with drug selection.
Ubiquitination and deubiquitination assays
In vitro and in vivo deubiquitination assays using K63-linked ubiquitin chains can measure the catalytic activity of DUBs. These assays often employ immunoprecipitation followed by immunoblotting with linkage-specific ubiquitin antibodies [2,3]. They are essential to confirm that a candidate DUB directly removes K63-linked chains from a substrate.
Proteomics and interactomics
Mass spectrometry-based proteomics can identify DUB substrates and interaction partners. For instance, affinity purification of USP10 followed by mass spectrometry revealed ANLN as a substrate. Similarly, interactome studies can uncover adaptors that enhance K63-linked deubiquitination.
Functional validation with knockout and overexpression models
CRISPR knockout and overexpression cell lines are used to validate the functional impact of DUBs on substrate stability and downstream phenotypes. For example, USP3 knockout reduced SMARCA5 stability and sensitized prostate cancer cells to chemotherapy. Overexpression of UCHL1 stabilized Twist1 and promoted metastasis in NSCLC models.
How CRISPR Can Be Used to Study GO:1903006 positive regulation of protein K63-linked deubiquitination
Knockout
CRISPR knockout of DUBs such as USP1, USP3, or USP10 can abolish K63-linked deubiquitination of specific substrates, leading to their degradation or functional loss [1,2,3]. These models are invaluable for assessing the causal role of a DUB in drug resistance and tumor growth.
Point Mutation
Introducing point mutations in the catalytic domain of a DUB (e.g., USP3) can separate its deubiquitinase activity from scaffolding functions. Such models help determine whether the enzymatic activity is required for stabilizing substrates like SMARCA5.
Knock-in
Knock-in of tagged or mutant DUBs (e.g., STAMBPL1) allows precise tracking of protein interactions and substrate specificity. Tagged knock-in models can be used for affinity purification and live-cell imaging.
Overexpression
Overexpression of DUBs such as UCHL1 or STAMBPL1 can mimic oncogenic conditions, driving substrate stabilization and phenotypic changes like metastasis or EGFR activation [4,5]. These models are useful for gain-of-function studies and drug testing.
How EDITGENE Supports positive regulation of protein K63-linked deubiquitination Research
Researchers studying positive regulation of protein K63-linked deubiquitination-related genes often need to determine whether a candidate gene is causally involved in substrate stabilization, drug resistance, or tumor progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of protein K63-linked deubiquitination research.
Frequently Asked Questions About positive regulation of protein K63-linked deubiquitination
What is GO:1903006?
GO:1903006 is the Gene Ontology term for positive regulation of protein K63-linked deubiquitination, defined as any process that activates or increases the removal of K63-linked ubiquitin chains from a target protein.
What genes are involved in positive regulation of protein K63-linked deubiquitination?
Key genes include USP1, USP3, USP10, UCHL1, STAMBPL1, and TRIM35, which encode deubiquitinases or regulatory proteins [1,2,3,4,5,8].
How does K63-linked deubiquitination affect cancer?
It stabilizes oncogenic proteins such as MAST1, SMARCA5, TOE1, Twist1, and ERα, contributing to drug resistance, metastasis, and endocrine resistance [1,3,4,5,7].
What is the role of USP1 in K63-linked deubiquitination?
USP1 removes K63-linked ubiquitin from MAST1, stabilizing it and promoting cisplatin resistance in cancer cells.
How is K63-linked deubiquitination regulated?
It is regulated by DUB expression, post-translational modifications, and feedback loops such as the MYC-STAMBPL1-TOE1 axis.
What experimental models are used to study K63-linked deubiquitination?
CRISPR knockout, point mutation, knock-in, and overexpression cell lines, along with ubiquitination assays and proteomics [1,2,3,4,5].
What diseases are associated with dysregulated K63-linked deubiquitination?
Cancers including prostate, breast, lung, esophageal, and hepatocellular carcinoma, as well as immune disorders [1,2,3,4,5,7,8].
How can CRISPR screening identify regulators of K63-linked deubiquitination?
Genome-wide CRISPR screens can knock out each gene and measure effects on substrate stability or drug sensitivity, as shown for USP1.
What is the difference between K63-linked and K48-linked deubiquitination?
K63-linked chains typically regulate signaling and stability without targeting for proteasomal degradation, whereas K48-linked chains often mark proteins for degradation [2,3].
Can EDITGENE help with my research on GO:1903006?
Yes, EDITGENE provides knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services tailored to study K63-linked deubiquitination [1,3,4].
Conclusion
GO:1903006, positive regulation of protein K63-linked deubiquitination, is a critical biological process that controls protein stability and signaling in health and disease. The DUBs and regulatory loops described here offer promising targets for therapeutic intervention in cancer and immune disorders [1,2,3,4,5,7,8]. Leveraging CRISPR-based models and functional genomics will continue to unravel the complexities of this process and facilitate drug discovery [1,6].
References
- 1. Tyagi A et al.. 2022. CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells.. Theranostics 12(13):5949-5970 PMID: 35966591
- 2. Cao YF et al.. 2023. Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.. Cell Death Differ 30(2):527-543 PMID: 36526897
- 3. Li S et al.. 2024. USP3 promotes DNA damage response and chemotherapy resistance through stabilizing and deubiquitinating SMARCA5 in prostate cancer.. Cell Death Dis 15(11):790 PMID: 39500888
- 4. Zhang H et al.. 2024. A MYC-STAMBPL1-TOE1 positive feedback loop mediates EGFR stability in hepatocellular carcinoma.. Cell Rep 43(10):114812 PMID: 39388352
- 5. Feng Q et al.. 2025. UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination to drive tumor metastasis in non-small cell lung cancer.. Cell Death Discov 12(1):60 PMID: 41469388
- 6. Tomomatsu S et al.. 2025. Polyubiquitin architecture editing on collided ribosomes maintains persistent RQC activity.. EMBO J 44(21):6051-6077 PMID: 40957981
- 7. Li H et al.. 2025. ARL3 Enhances ERα Stability via USP10 Deubiquitination to Promote Endocrine Resistance and Drive Mitochondrial Metabolic Reprogramming in HR+ Breast Cancer.. Adv Sci (Weinh) 12(47):e09769 PMID: 41047477
- 8. Zhang J et al.. 2025. TRIM35 Negatively Regulates the cGAS-STING-Mediated Signaling Pathway by Attenuating K63-Linked Ubiquitination of STING.. Inflammation 48(2):855-869 PMID: 39088122
